Upfront Gamma Knife radiosurgery for Cushing’s disease and acromegaly: a multicenter, international study

Restricted access

OBJECTIVE

Gamma Knife radiosurgery (GKS) is typically used after failed resection in patients with Cushing’s disease (CD) and acromegaly. Little is known about the upfront role of GKS for patients with CD and acromegaly. In this study, the authors examine the outcome of upfront GKS for patients with these functioning adenomas.

METHODS

An international group of 7 Gamma Knife centers sent pooled data from 46 patients (21 with CD and 25 with acromegaly) undergoing upfront GKS to the coordinating center of the study for analysis. Diagnosis was established on the basis of clinical, endocrine, and radiological studies. All patients were treated on a common radiosurgical platform and longitudinally followed for tumor control, endocrine remission, and hypopituitarism. Patients received a tumor median margin dose of 25 Gy (range 12–40.0 Gy) at a median isodose of 50%.

RESULTS

The median endocrine follow-up was 69.5 months (range 9–246 months). Endocrine remission was achieved in 51% of the entire cohort, with 28% remission in acromegaly and 81% remission for those with CD at the 5-year interval. Patients with CD achieved remission earlier as compared to those with acromegaly (p = 0.0005). In patients post-GKS, the pituitary adenoma remained stable (39%) or reduced (61%) in size. Hypopituitarism occurred in 9 patients (19.6%), and 1 (2.2%) developed third cranial nerve (CN III) palsy. Eight patients needed further intervention, including repeat GKS in 6 and transsphenoidal surgery in 2.

CONCLUSIONS

Upfront GKS resulted in good tumor control as well as a low rate of adverse radiation effects in the whole group. Patients with CD achieved a faster and far better remission rate after upfront GKS in comparison to patients with acromegaly. GKS can be considered as an upfront treatment in carefully selected patients with CD who are unwilling or unable to undergo resection, but it has a more limited role in acromegaly.

ABBREVIATIONS ACTH = adrenocorticotropic hormone; CD = Cushing’s disease; CN = cranial nerve; CS = cavernous sinus; GH = growth hormone; GKS = Gamma Knife radiosurgery; IGF-I = insulin-like growth factor–I; SRS = stereotactic radiosurgery; UFC = urinary free cortisol.

Article Information

Correspondence Jason P. Sheehan: University of Virginia Health System, Charlottesville, VA. jsheehan@virginia.edu.

INCLUDE WHEN CITING Published online August 17, 2018; DOI: 10.3171/2018.3.JNS18110.

Disclosures Dr. Lunsford reports stock ownership in Elekta AB. He is also on the Data and Safety Monitoring Board for Insightec.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Kaplan-Meier plot showing that actuarial endocrine remission rates after GKS for the entire study cohort at 1, 2, 3, and 5 years were 23%, 35%, 42%, and 51%, respectively. The number with follow-up at 1, 2, 3, and 5 years was 33, 27, 22, and 14 patients, respectively.

  • View in gallery

    Kaplan-Meier plot demonstrating differential endocrine remission rates after upfront GKS in patients with adenoma secreting GH and CD. Patients with CD were more likely to achieve remission (p = 0.0005) than those with acromegaly. The number with follow-up at 1, 2, 3, and 5 years was 10, 6, 4, and 2 patients, respectively, for CD and 25, 21, 17, and 12 patients, respectively, for acromegaly.

References

1

Aghi MKPetit JChapman PLoeffler JKlibanski ABiller BM: Management of recurrent and refractory Cushing’s disease with reoperation and/or proton beam radiosurgery. Clin Neurosurg 55:1411442008

2

Ayuk JSheppard MC: Does acromegaly enhance mortality? Rev Endocr Metab Disord 9:33392008

3

Blevins LS JrChristy JHKhajavi MTindall GT: Outcomes of therapy for Cushing’s disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 83:63671998

4

Buchfelder MNistor RFahlbusch RHuk WJ: The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropic hormone-secreting adenomas in Cushing disease. AJNR Am J Neuroradiol 14:118311901993

5

Castinetti FNagai MDufour HKuhn JMMorange IJaquet P: Gamma knife radiosurgery is a successful adjunctive treatment in Cushing’s disease. Eur J Endocrinol 156:91982007

6

Castinetti FNagai MMorange IDufour HCaron PChanson P: Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 94:340034072009

7

Castinetti FRégis JDufour HBrue T: Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 6:2142232010

8

Chandler WFSchteingart DELloyd RVMcKeever PEIbarra-Perez G: Surgical treatment of Cushing’s disease. J Neurosurg 66:2042121987

9

Colao AAuriemma RSRebora AGaldiero MResmini EMinuto F: Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 71:2372452009

10

Davies BMCarr ESoh CGnanalingham KK: Assessing size of pituitary adenomas: a comparison of qualitative and quantitative methods on MR. Acta Neurochir (Wien) 158:6776832016

11

Devin JKAllen GSCmelak AJDuggan DMBlevins LS: The efficacy of linear accelerator radiosurgery in the management of patients with Cushing’s disease. Stereotact Funct Neurosurg 82:2542622004

12

Friedman RBOldfield EHNieman LKChrousos GPDoppman JLCutler GB Jr: Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg 71:5205271989

13

Giustina ABronstein MDCasanueva FFChanson PGhigo EHo KK: Current management practices for acromegaly: an international survey. Pituitary 14:1251332011

14

Grant RAWhicker MLleva RKnisely JPInzucchi SEChiang VL: Efficacy and safety of higher dose stereotactic radiosurgery for functional pituitary adenomas: a preliminary report. World Neurosurg 82:1952012014

15

Hammer GDTyrrell JBLamborn KRApplebury CBHannegan ETBell S: Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab 89:634863572004

16

Jagannathan JSheehan JPPouratian NLaws ERSteiner LVance ML: Gamma Knife surgery for Cushing’s disease. J Neurosurg 106:9809872007

17

Kim SHHuh RChang JWPark YGChung SS: Gamma Knife radiosurgery for functioning pituitary adenomas. Stereotact Funct Neurosurg 72 (Suppl 1):1011101999

18

Lee CCKano HYang HCXu ZYen CPChung WY: Initial Gamma Knife radiosurgery for nonfunctioning pituitary adenomas. J Neurosurg 120:6476542014

19

Lee CCVance MLXu ZYen CPSchlesinger DDodson B: Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab 99:127312812014

20

Marek JJežková JHána VKršek MLiščák RVladyka V: Gamma knife radiosurgery for Cushing’s disease and Nelson’s syndrome. Pituitary 18:3763842015

21

Mayo CMartel MKMarks LBFlickinger JNam JKirkpatrick J: Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 76 (3 Suppl):S28S352010

22

Mehta GUDing DPatibandla MRKano HSisterson NSu YH: Stereotactic radiosurgery for Cushing disease: results of an international, multicenter study. J Clin Endocrinol Metab 102:428442912017

23

Nakane TKuwayama AWatanabe MTakahashi TKato TIchihara K: Long term results of transsphenoidal adenomectomy in patients with Cushing’s disease. Neurosurgery 21:2182221987

24

Park YGChang JWKim EYChung SS: Gamma knife surgery in pituitary microadenomas. Yonsei Med J 37:1651731996

25

Patil CGLad SPHarsh GRLaws ER JrBoakye M: National trends, complications, and outcomes following transsphenoidal surgery for Cushing’s disease from 1993 to 2002. Neurosurg Focus 23(3):E72007

26

Patil CGPrevedello DMLad SPVance MLThorner MOKatznelson L: Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93:3583622008

27

Patil CGVeeravagu APrevedello DMKatznelson LVance MLLaws ER Jr: Outcomes after repeat transsphenoidal surgery for recurrent Cushing’s disease. Neurosurgery 63:2662712008

28

Prevedello DMPouratian NSherman JJane JA JrVance MLLopes MB: Management of Cushing’s disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg 109:7517592008

29

Ram ZNieman LKCutler GB JrChrousos GPDoppman JLOldfield EH: Early repeat surgery for persistent Cushing’s disease. J Neurosurg 80:37451994

30

Renehan AGO’Connell JO’Halloran DShanahan FPotten CSO’Dwyer ST: Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res 35:7127252003

31

Schlesinger DSnell JSheehan J: Shielding strategies for Gamma Knife surgery of pituitary adenomas. J Neurosurg 105 (Suppl):2412482006

32

Seo YFukuoka STakanashi MSasaki TSuematsu KNakamura J: Gamma knife surgery for Cushing’s disease. Surg Neurol 43:1701761995

33

Sheehan JMVance MLSheehan JPEllegala DBLaws ER Jr: Radiosurgery for Cushing’s disease after failed transsphenoidal surgery. J Neurosurg 93:7387422000

34

Sheehan JPNiranjan ASheehan JMJane JA JrLaws ERKondziolka D: Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 102:6786912005

35

Sheehan JPXu ZLobo MJ: External beam radiation therapy and stereotactic radiosurgery for pituitary adenomas. Neurosurg Clin N Am 23:5715862012

36

Sheehan JPXu ZSalvetti DJSchmitt PJVance ML: Results of gamma knife surgery for Cushing’s disease. J Neurosurg 119:148614922013

37

Snell JWSheehan JStroila MSteiner L: Assessment of imaging studies used with radiosurgery: a volumetric algorithm and an estimation of its error. Technical note. J Neurosurg 104:1571622006

38

Starke RMWilliams BJVance MLSheehan JP: Radiation therapy and stereotactic radiosurgery for the treatment of Cushing’s disease: an evidence-based review. Curr Opin Endocrinol Diabetes Obes 17:3563642010

39

Symon LLogue VMohanty S: Recurrence of pituitary adenomas after transcranial operation. J Neurol Neurosurg Psychiatry 45:7807851982

40

Tinnel BAHenderson MAWitt TCFakiris AJWorth RMDes Rosiers PM: Endocrine response after gamma knife-based stereotactic radiosurgery for secretory pituitary adenoma. Stereotact Funct Neurosurg 86:2922962008

41

Wilson PJDe-Loyde KJWilliams JRSmee RI: Acromegaly: a single centre’s experience of stereotactic radiosurgery and radiotherapy for growth hormone secreting pituitary tumours with the linear accelerator. J Clin Neurosci 20:150615132013

42

Wilson PJOmay SBKacker AAnand VKSchwartz TH: Endonasal endoscopic pituitary surgery in the elderly. J Neurosurg 128:4294362018

43

Witt TC: Stereotactic radiosurgery for pituitary tumors. Neurosurg Focus 14(5):e102003

44

Xu ZLee Vance MSchlesinger DSheehan JP: Hypopituitarism after stereotactic radiosurgery for pituitary adenomas. Neurosurgery 72:630–637 6366372013

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 165 165 50
Full Text Views 367 367 23
PDF Downloads 147 147 13
EPUB Downloads 0 0 0

PubMed

Google Scholar